首页> 美国卫生研究院文献>PLoS Clinical Trials >CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2
【2h】

CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2

机译:CS-SELEX产生高亲和力的ssDNA适体作为丙型肝炎病毒包膜糖蛋白E2的分子探针

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Currently, the development of effective diagnostic reagents as well as treatments against Hepatitis C virus (HCV) remains a high priority. In this study, we have described the development of an alive cell surface -Systematic Evolution of Ligands by Exponential Enrichment (CS-SELEX) technique and screened the functional ssDNA aptamers that specifically bound to HCV envelope surface glycoprotein E2. Through 13 rounds of selection, the CS-SELEX generated high-affinity ssDNA aptamers, and the selected ssDNA aptamer ZE2 demonstrated the highest specificity and affinity to E2-positive cells. HCV particles could be specifically captured and diagnosed using the aptamer ZE2. A good correlation was observed in HCV patients between HCV E2 antigen-aptamer assay and assays for HCV RNA quantities or HCV antibody detection. Moreover, the selected aptamers, especially ZE2, could competitively inhibit E2 protein binding to CD81, an important HCV receptor, and significantly block HCV cell culture (HCVcc) infection of human hepatocytes (Huh7.5.1) in vitro. Our data demonstrate that the newly selected ssDNA aptamers, especially aptamer ZE2, hold great promise for developing new molecular probes, as an early diagnostic reagent for HCV surface antigen, or a therapeutic drug specifically for HCV.
机译:当前,开发有效的诊断试剂以及抗丙型肝炎病毒(HCV)的治疗仍然是高度优先事项。在这项研究中,我们已经描述了通过指数富集(CS-SELEX)技术开发的活细胞表面-配体的系统进化,并筛选了特异性结合HCV包膜表面糖蛋白E2的功能性ssDNA适体。通过13轮选择,CS-SELEX产生了高亲和力的ssDNA适体,并且所选的ssDNA适体ZE2对E2阳性细胞表现出最高的特异性和亲和力。 HCV颗粒可以使用适体ZE2专门捕获和诊断。在HCV患者中,HCV E2抗原-适体测定与HCV RNA量测定或HCV抗体检测之间存在良好的相关性。此外,选定的适体,尤其是ZE2,可以竞争性地抑制E2蛋白与重要的HCV受体CD81的结合,并在体外显着阻断HCV细胞培养(HCVcc)对人肝细胞(Huh7.5.1)的感染。我们的数据表明,新选择的ssDNA适体,尤其是适体ZE2,有望开发出新的分子探针,作为HCV表面抗原的早期诊断试剂,或专为HCV的治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号